MK-2870 Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)

Conditions: Non-small Cell Lung Cancer (NSCLC) Interventions: Biological: MK-2870; Drug: Docetaxel; Drug: Pemetrexed Sponsors: Merck Sharp& Dohme LLC Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials